Join this webinar with Drs. Susumu Sakimoto and Valentina Marchetti as they discuss their current work on generating human endothelial colony-forming cells (ECFCs) under xeno-free conditions to treat vascular abnormalities in the eye. Vascular abnormalities are a common component of eye diseases that often lead to vision loss. It is possible to use one cell type to rescue another cell type in the face of severe stress. In this webinar, Dr. Susumu Sakimoto will present his study on how human ECFCs injected into the vitreous cavity rescue vaso-obliteration and neurodegeneration in animal models of retinal disease. These results help us understand the mechanism of ECFC-based therapies for ischemic insults and retinal neurodegenerative diseases. Dr. Valentina Marchetti will present a workflow to derive and expand ECFCs under xeno-free conditions using the EC-Cult™-XF ECFC Culture Kit.
Department of Ophthalmology
Osaka Graduate School of Medicine
Susumu Sakimoto completed his MD at Nagasaki University in 2003, and his PhD in Cell Biology and Biomedicine from the Graduate School of Medicine at Osaka University, Japan in 2012. He then moved to the United States to join Professor Martin Friedlander’s laboratory at the Scripps Research Institute as a Postdoctoral Research Fellow. In the Friedlander’s laboratory, Dr. Sakimoto’s research focus was to study the biology of endothelial colony-forming cells (ECFCs) and their therapeutic potential for various eye disease model. Dr. Sakimoto is currently an Assistant Professor at the Department of Ophthalmology at the Osaka Graduate School of Medicine.
Valentina Marchetti completed her PhD in Physiopathology from the University of Rome, Italy. Her research focused on endothelial dysfunction in cardiovascular diseases and diabetes. She then moved to United States, where she worked as a Postdoctoral Research Fellow at The Scripps Research Institute, in the laboratory of Professor Martin Friedlander. Using in vivo animal model of diabetes she studied the usage of endothelial progenitor cells as innovative therapy for treatment of ischemic and neuro-degenerative retinopathies. Valentina is currently a Senior Scientist at STEMCELL Technologies working on the development of a complete new line of products to support endothelial cell research.
Upcoming Webinar: Therapeutic Application of Endothelial Colony-Forming Cells for Retinal Diseases
Wednesday, February 14, 2018 | 10 AM PST | 1 PM EST | 6 PM UTC
If you are unable to attend the live webinar, please register and we will send you a link to view the recording when it becomes available.
- Retinal vascular repair upon intravitreal injection of ECFCs in a murine model with ischemic retinopathy is observed.
- A subpopulation of intravitreally injected ECFCs expressing CD44 modulates retinal revascularization in both ischemic retinopathy and late-onset retinal degeneration.
- Xeno-free media to derive and expand ECFCs will be important in the development of cell-based therapies.
- Workflow overview on the derivation and expansion of ECFCs from human cord blood using xeno-free medium and reagents.